Keyphrases
Anthracyclines
100%
Doxorubicin
100%
Equivalence Ratio
100%
Anthraquinone
100%
Late-onset Cardiotoxicity
100%
Cardiomyopathy
72%
Mitoxantrone
72%
Epirubicin
54%
Daunorubicin
54%
Idarubicin
36%
Cancer Diagnosis
27%
Childhood Cancer Survivors
18%
Chest Radiotherapy
18%
Oncology
9%
Pediatric Oncology
9%
Life-threatening
9%
Dutch
9%
Survivors
9%
Hazard Ratio
9%
Children's Oncology Group
9%
Cardiotoxicity
9%
Childhood Cancer Survivor Study
9%
Cumulative Dose
9%
Optimal Dose
9%
Medical Records
9%
Treatment Group
9%
Cancer Treatment Protocols
9%
Late-onset
9%
Dose-response Relationship
9%
Multicenter Cohort Study
9%
Cox Proportional Hazards Model
9%
Hematologic
9%
Oncological Treatment
9%
Hematotoxicity
9%
Linear Dose Response
9%
Ratio-based
9%
Paediatric Cancer Treatment
9%
Weighted Mean
9%
Linear-exponential
9%
Dose Equivalence
9%
Exponential Model
9%
Substitution Rules
9%
Equivalency
9%
Lifetime Study
9%
Pharmacology, Toxicology and Pharmaceutical Science
Anthracycline
100%
Doxorubicin
100%
Cardiotoxicity
100%
Anthraquinone
100%
Mitoxantrone
72%
Myocardial Disease
72%
Epirubicin
54%
Daunorubicin
54%
Malignant Neoplasm
36%
Childhood Cancer
36%
Idarubicin
36%
Cohort Study
9%
Dose-Response Relationship
9%